Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.00    1.00 (1.43%)
Bid:
70.00
Ask:
72.00
Spread: 2.00 (2.857%)
Market Cap: £323.13m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Appointment

9 Nov 2007 16:59

Avacta Group plc Board Appointment

Avacta Group plc ("Avacta" or the "Company"), which develops detection and analysis technology aimed at the biopharmaceutical, defence & security and clinical diagnostics markets, is pleased to announce the appointment of Russell Hodgetts to the Board of Directors, with effect from 10 July 2007.

Russell Winston Hodgetts, 36, has been Chief Operating Officer of Avacta since October 2005, and has a wealth of experience in strategic business development and group operations. Prior to joining Avacta he worked for Techtran Group Limited where he helped guide the commercialization and business development of companies created from University of Leeds research and intellectual property.

He currently oversees the development of the analytical services division of the Company in addition to being responsible for group operations.

Russell Hodgetts is the beneficial owner of 9,847,912 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"), representing approximately 1.27 per cent. of the issued share capital of the Company and 1,804,568 options to acquire Ordinary Shares at an exercise price of 2.25p per share.

He is also a director of Avacta Analytical Limited.

Russell Hodgetts was named Russell Beckett until family circumstances led to his name being changed when aged 11.

There are no other disclosures required by paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:

"Russell has been an integral part of the development of Avacta over the past two years and his focus on continued growth has been central to the success of Avacta Analytical Ltd. We are pleased to welcome him to the Board and will continue to draw on his knowledge and drive to ensure that Avacta maintains its current path of development and innovation."

9 November 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Limited Tel: 020 7562 4713 Henry Turcan/Michael Brennan Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk

AVACTA GROUP PLC
Date   Source Headline
30th Jun 20253:00 pmRNSAppointment of Zeus Capital as Joint Broker
19th Jun 20257:00 amRNSNew Response in Phase 1b Trial
9th Jun 20255:15 pmRNSPosting of Annual Report and Revised Notice of AGM
6th Jun 20257:00 amRNSPreliminary Full Year 2024 Results
4th Jun 20257:00 amRNSAvacta Change in Prelim Date Part 2
28th May 20257:00 amRNSBoard appointments
27th May 20257:00 amRNSUpdate on timing of preliminary results
15th May 20257:00 amRNSNotice of Results
12th May 202512:00 pmRNS-RInvestor Webinar
8th May 20257:30 amRNSBlock Listing Application to AIM
29th Apr 20257:00 amRNSBoard change
28th Apr 20255:52 pmRNSBlock Listing Six Monthly Return
28th Apr 20257:01 amRNSAvacta presents preclinical data at AACR
28th Apr 20257:00 amRNSAvacta presents data from lead candidate at AACR
23rd Apr 20257:00 amRNSIssue of Equity and Total Voting Rights
31st Mar 20257:00 amRNSAvacta Quarterly Update
26th Mar 20257:00 amRNSAvacta Announces Presentations at AACR
25th Mar 20257:00 amRNSAvacta Completes Launch Diagnostics Sale
10th Mar 20257:00 amRNSAvacta to Present at Leerink Healthcare Conference
7th Mar 20258:40 amRNSAvacta announces data update for AVA6000
7th Mar 20257:42 amRNSAvacta to sell Launch Diagnostics
4th Feb 20257:00 amRNSAppointment of Joint Broker
21st Jan 20253:09 pmRNSIssue of Equity and Total Voting Rights
16th Jan 20257:00 amRNSAvacta Announces Data from AVA6000 Phase 1 trial
13th Jan 20257:00 amRNSAvacta Appoints Chief Financial Officer
12th Dec 20247:00 amRNSCompletion of Dose Escalation and RDE Arms
30th Oct 20247:00 amRNSR&D Spotlight focusing on pipeline advances
28th Oct 20247:00 amRNSBlock Listing Six Monthly Return
24th Oct 20247:00 amRNSAvacta Reports Pipeline Avances at EORTC
21st Oct 20244:00 pmRNSIssue of Equity and Total Voting Rights
21st Oct 20247:00 amRNSAvacta and Tempus Enter Strategic Collaboration
17th Oct 20247:00 amRNSAvacta Expands its Pipeline
15th Oct 20247:00 amRNSAvacta appoints Chief Scientific Officer
10th Oct 20247:00 amRNSAvacta Unveils Pipeline Expansion at EORTC 2024
30th Sep 20247:00 amRNSInterim Results
16th Sep 20247:00 amRNSAvacta Reported Updated Phase 1 Data of AVA6000
12th Sep 20247:00 amRNSNotice of Results
9th Sep 20247:00 amRNSAvacta to present clinical data at ESMO Congress
2nd Sep 20243:53 pmRNSDirector/PDMR Shareholdings and TVR
18th Jul 20247:00 amRNSConvertible Bond Payment
26th Jun 20242:46 pmRNSResult of AGM
26th Jun 20247:00 amRNSAGM Business Update
20th Jun 20247:00 amRNSShaun Chilton appointed Non-Executive Chairman
11th Jun 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
31st May 20247:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20247:00 amRNSSuccessful Completion of First Cohort
30th Apr 20247:01 amRNSFull Year Results
30th Apr 20247:00 amRNSBoard Change
26th Apr 20249:51 amRNSBlock listing Interim Return REPLACEMENT
26th Apr 20247:00 amRNSBlock Listing Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.